HDAC6 regulates neuroblastoma cell migration and may play a role in the invasion process

References

• Brodeur GM, Pritchard J, Berthold F, Carlsen NL, Castel V, Castelberry RP, De Bernardi B, Evans AE, Favrot M, Hedborg F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 1993; 11:1466-77; PMID:8336186
   PubMed Web of Science ®Google Scholar
• Schor NF. New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence. Pharmacol Ther 2009; 122:44-55; PMID:19318043
   PubMed Web of Science ®Google Scholar
• Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003; 3:203-16; PMID:12612655
   PubMed Web of Science ®Google Scholar
• Cotterill SJ, Pearson AD, Pritchard J, Kohler JA, Foot AB, European Neuroblastoma Study G, United Kingdom Children's Cancer Study G. Late relapse and prognosis for neuroblastoma patients surviving 5 years or more: a report from the European Neuroblastoma Study Group "Survey". Med Pediatr Oncol 2001; 36:235-8; PMID:11464893
   PubMedGoogle Scholar
• Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202-11; PMID:20558371
   PubMed Web of Science ®Google Scholar
• Aronson MR, Smoker WR, Oetting GM. Hemorrhagic intracranial parenchymal metastases from primary retroperitoneal neuroblastoma. Pediatr Radiol 1995; 25:284-5; PMID:7567239
   PubMed Web of Science ®Google Scholar
• Ara T, DeClerck YA. Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev 2006; 25:645-57; PMID:17160711
   PubMed Web of Science ®Google Scholar
• Palmer TD, Ashby WJ, Lewis JD, Zijlstra A. Targeting tumor cell motility to prevent metastasis. Adv Drug Deliv Rev 2011; 63:568-81; PMID:21664937
   PubMed Web of Science ®Google Scholar
• Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2013; 34:283-9; PMID:23571046
   PubMed Web of Science ®Google Scholar
• Lauffenburger DA. Cell motility. Making connections count. Nature 1996; 383:390-1; PMID:8837766
   PubMed Web of Science ®Google Scholar
• Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell 1996; 84:359-69; PMID:8608589
   PubMed Web of Science ®Google Scholar
• Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF, Yao TP. HDAC6 is a microtubule-associated deacetylase. Nature 2002; 417:455-8; PMID:12024216
   PubMed Web of Science ®Google Scholar
• Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, et al. HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell 2007; 27:197-213; PMID:17643370
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C, Turner BM. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005; 19:1751-9; PMID:16121216
   PubMed Web of Science ®Google Scholar
• Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, Tanzawa H. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006; 29:117-24; PMID:16773191
   PubMed Web of Science ®Google Scholar
• Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J, Roden RB. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res 2008; 14:7340-7; PMID:19010849; http://dx.doi.org/10.1158/1078-0432.CCR-08-0642
   PubMed Web of Science ®Google Scholar
• Li D, Sun X, Zhang L, Yan B, Xie S, Liu R, Liu M, Zhou J. Histone deacetylase 6 and cytoplasmic linker protein 170 function together to regulate the motility of pancreatic cancer cells. Protein Cell 2013.
   Web of Science ®Google Scholar
• Berridge MV, Herst PM, Tan AS. Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 2005; 11:127-52; PMID:16216776; http://dx.doi.org/10.1016/S1387-2656(05)11004-7
   PubMedGoogle Scholar
• Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006; 1:1112-6; PMID:17406391; http://dx.doi.org/10.1038/nprot.2006.179
   PubMed Web of Science ®Google Scholar
• Huttenlocher A, Palecek SP, Lu Q, Zhang W, Mellgren RL, Lauffenburger DA, Ginsberg MH, Horwitz AF. Regulation of cell migration by the calcium-dependent protease calpain. J Biol Chem 1997; 272:32719-22; PMID:9407041; http://dx.doi.org/10.1074/jbc.272.52.32719
   PubMed Web of Science ®Google Scholar
• Verdel A, Curtet S, Brocard MP, Rousseaux S, Lemercier C, Yoshida M, Khochbin S. Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm. Curr Biol 2000; 10:747-9; PMID:10873806; http://dx.doi.org/10.1016/S0960-9822(00)00542-X
   PubMed Web of Science ®Google Scholar
• Aldana-Masangkay GI, Sakamoto KM. The role of HDAC6 in cancer. J Biomed Biotechnol 2011; 2011:875824; PMID:21076528; http://dx.doi.org/10.1155/2011/875824
   PubMed Web of Science ®Google Scholar
• Saji S, Kawakami M, Hayashi S, Yoshida N, Hirose M, Horiguchi S, Itoh A, Funata N, Schreiber SL, Yoshida M, et al. Significance of HDAC6 regulation via estrogen signaling for cell motility and prognosis in estrogen receptor-positive breast cancer. Oncogene 2005; 24:4531-9; PMID:15806142; http://dx.doi.org/10.1038/sj.onc.1208646
   PubMed Web of Science ®Google Scholar
• Tran AD, Marmo TP, Salam AA, Che S, Finkelstein E, Kabarriti R, Xenias HS, Mazitschek R, Hubbert C, Kawaguchi Y, et al. HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. J Cell Sci 2007; 120:1469-79; PMID:17389687; http://dx.doi.org/10.1242/jcs.03431
   PubMed Web of Science ®Google Scholar
• Coffey DC, Kutko MC, Glick RD, Swendeman SL, Butler L, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol 2000; 35:577-81; PMID:11107121; http://dx.doi.org/10.1002/1096-911X(20001201)35:6
   PubMedGoogle Scholar
• Coffey DC, Kutko MC, Glick RD, Butler LM, Heller G, Rifkind RA, Marks PA, Richon VM, La Quaglia MP. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res 2001; 61:3591-4; PMID:11325825
   PubMed Web of Science ®Google Scholar
• Tang XX, Robinson ME, Riceberg JS, Kim DY, Kung B, Titus TB, Hayashi S, Flake AW, Carpentieri D, Ikegaki N. Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma. Clin Cancer Res 2004; 10:5837-44; PMID:15355914; http://dx.doi.org/10.1158/1078-0432.CCR-04-0395
   PubMed Web of Science ®Google Scholar
• Ouwehand K, de Ruijter AJ, van Bree C, Caron HN, van Kuilenburg AB. Histone deacetylase inhibitor BL1521 induces a G1-phase arrest in neuroblastoma cells through altered expression of cell cycle proteins. FEBS Lett 2005; 579:1523-8; PMID:15733867; http://dx.doi.org/10.1016/j.febslet.2005.01.058
   PubMed Web of Science ®Google Scholar
• Subramanian C, Opipari AW, Jr., Bian X, Castle VP, Kwok RP. Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2005; 102:4842-7; PMID:15778293; http://dx.doi.org/10.1073/pnas.0408351102
   PubMed Web of Science ®Google Scholar
• Subramanian C, Jarzembowski JA, Opipari AW, Jr., Castle VP, Kwok RP. CREB-binding protein is a mediator of neuroblastoma cell death induced by the histone deacetylase inhibitor trichostatin A. Neoplasia 2007; 9:495-503; PMID:17603632; http://dx.doi.org/10.1593/neo.07262
   PubMed Web of Science ®Google Scholar
• Muhlethaler-Mottet A, Meier R, Flahaut M, Bourloud KB, Nardou K, Joseph JM, Gross N. Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells. Mol Cancer 2008; 7:55; PMID:18549473
   PubMed Web of Science ®Google Scholar
• Francisco R, Perez-Perarnau A, Cortes C, Gil J, Tauler A, Ambrosio S. Histone deacetylase inhibition induces apoptosis and autophagy in human neuroblastoma cells. Cancer Lett 2012; 318:42-52; PMID:22186300
   PubMed Web of Science ®Google Scholar
• Zhan Q, Tsai S, Lu Y, Wang C, Kwan Y, Ngai S. RuvBL2 is involved in histone deacetylase inhibitor PCI-24781-induced cell death in SK-N-DZ neuroblastoma cells. PLoS One 2013; 8:e71663; PMID:23977108
   PubMed Web of Science ®Google Scholar
• Subramanian C, Jarzembowski JA, Opipari AW, Jr., Castle VP, Kwok RP. HDAC6 deacetylates Ku70 and regulates Ku70-Bax binding in neuroblastoma. Neoplasia 2011; 13:726-34; PMID:21847364
   PubMed Web of Science ®Google Scholar
• Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003; 100:4389-94; PMID:12677000
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38-51; PMID:16397526
   PubMed Web of Science ®Google Scholar
• Karagiannis TC, El-Osta A. Will broad-spectrum histone deacetylase inhibitors be superseded by more specific compounds? Leukemia 2007; 21:61-5; PMID:17109024
   PubMed Web of Science ®Google Scholar
• Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, Anderson KC. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005; 102:8567-72; PMID:15937109
   PubMed Web of Science ®Google Scholar
• Shan B, Yao TP, Nguyen HT, Zhuo Y, Levy DR, Klingsberg RC, Tao H, Palmer ML, Holder KN, Lasky JA. Requirement of HDAC6 for transforming growth factor-beta(1)-induced epithelial-mesenchymal transition. J Biol Chem 2008; 283:21065-73; PMID:18499657
   PubMed Web of Science ®Google Scholar
• Kawada J, Zou P, Mazitschek R, Bradner JE, Cohen JI. Tubacin kills Epstein-Barr virus (EBV)-Burkitt lymphoma cells by inducing reactive oxygen species and EBV lymphoblastoid cells by inducing apoptosis. J Biol Chem 2009; 284:17102-9; PMID:19386607
   PubMed Web of Science ®Google Scholar